Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. is a U.S.-based commercial-stage medical device company focused on chronic wound care. Its core product is Aurix, an autologous cell-based therapy platform used in wound healing settings, supported by related centrifuge devices, packaging, and distribution arrangements.

−73,4 %

66,9 %

−75,8 %

+142,7 %

1.06

0.89

— Nuo Therapeutics, Inc.
%
Aurix branded product70% The company's own branded autologous wound care product sold through its sales network.
Private label product15% Aurix supplied under Smith+Nephew's private label for U.S. distribution.
License and distribution fees7% Upfront and ongoing fees tied to the Smith+Nephew distribution agreement.
Centrifuge devices and related supplies8% Devices and supporting items used to prepare or deliver the Aurix therapy.

Nuo sells primarily to wound care providers, especially hospital outpatient wound care clinics and related clinical...

  • Hospital outpatient wound care clinicsprimary

    Buy Aurix for chronic wound treatment and clinical use after internal evaluation and reimbursement alignment.

  • Wound care providersprimary

    Clinics and providers that purchase the product to treat complex chronic wounds in outpatient settings.

  • Smith+Nephewsecondary

    Purchases private label Aurix product and supports distribution of Aurix-branded product to its customers.

  • Sales agents and distributorssecondary

    Third-party representatives that help generate orders and expand commercial coverage across U.S. markets.

  • Hospital value analysis committeessecondary

    Evaluate the product for clinical adoption and purchasing approval within hospital systems.

Nuo is centered on the United States, where it commercializes Aurix and builds its sales network...

  • •United States is the core commercial market
  • •Western U.S. coverage expanded through Pacific Medical agreement
  • •Sales are concentrated in hospital outpatient wound care clinics
  • •Smith+Nephew private label distribution is U.S.-based
  • •No disclosed country-level revenue outside the United States

Nuo's strategy is to expand adoption of Aurix in chronic wound care by building relationships with wound care providers...

01
Expand U.S. commercial coverageshort-term

Broader field coverage should increase awareness and access to Aurix among wound care providers.

02
Drive hospital adoption and reimbursement supportshort-term

Clinical approval and reimbursement execution are necessary for routine use in outpatient wound care.

03
Leverage Smith+Nephew distributionmedium-term

The partnership can extend reach and add a second commercialization channel for Aurix.

Nuo depends on successful reimbursement, clinical adoption, and execution by a relatively small commercial...

high

Reimbursement and coverage dependence

Aurix adoption relies on Medicare contractor administration and payer acceptance in wound care.

Scope
U.S. hospital outpatient wound care
Materiality
high
high

Commercial adoption risk

Hospitals and clinics must approve the product through value analysis and clinical review before broad use.

Scope
Hospital outpatient wound care clinics
Materiality
high
medium

Partner concentration risk

Smith+Nephew is an important distribution partner and private label customer.

Scope
U.S. private label distribution
Materiality
high
medium

Manufacturing and supply-chain risk

The company must manufacture, package, and ship product on time and at agreed transfer prices.

Scope
Private label product and centrifuge devices
Materiality
medium
Deferred revenue from Smith+Nephew upfront fee
Smooths revenue recognition versus cash receipt
Product revenue recognition
Impacts reported sales growth and gross profit
Inventory and device cost accounting
Affects cost of goods sold and margin profile
Commission and fulfillment expense accruals
Affects operating expense timing and comparability

Nu-Med Plus, Inc.

NUMD · Surgical & Medical Instruments & Apparatus

UNITED THERAPEUTICS Corp

UTHR · Pharmaceutical Preparations

Vera Therapeutics, Inc.

VERA · Pharmaceutical Preparations

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

Longduoduo Co Ltd

LDDD · Services-Health Services

: 29.4.2026